Seven secret ingredients for successfully launching and commercializing a biopharma’s first drug in Europe

Published on September 19, 2024

Navigating the shift from R&D to a commercially viable biopharma company presents unique challenges, especially when expanding into the European market. Our Simon-Kucher whitepaper offers essential insights for US-based biopharma companies aiming to achieve a successful transition. 

Drawing from extensive research—including over 20 case studies, approximately 4,500 data points, and insights from 18 industry experts—this whitepaper identifies critical factors for a successful first drug launch in Europe and explores: 

  • Characteristics of First Drug Launches in Europe: Key factors for successful independent launches, including drug, disease area, and company specifics. 
  • Opportunities and Reasons to Commercialize: Strategic motivations for launching a drug in Europe independently. 
  • The Seven Secret Ingredients for Success: Essential elements that maximize value…

    better market access

Continue reading on website
Other news

How to successfully build and launch a winning investment hybrid advice proposition

September 19, 2024
The hybrid advice model is experiencing a surge in popularity, particularly among younger customers, highlighting a clear customer need. This new model is prompting many direct-to-consumer (D2C) investment platforms to consider whether they should offer financial advice to their customers. Our experts reveal five noteworthy factors for success in building a hybrid advice proposition. At Simon Kuch

P&R brief Saudi Arabia: Navigating P&MA implications of the new SFDA economic guidelines

September 24, 2024
Aligned with Vision 2030 and the Saudi Ministry of Health’s national health transformation program, focused on creating a value-based healthcare system, the Saudi Food and Drug Authority (SFDA) has issued guidelines for the evaluation of economic studies. Its overall objective is to integrate pharmacoeconomic evaluation methods into the decision-making processes for pricing and reimbursement of no